東誠藥業(002675.SZ):下屬公司3020萬美元收購XING IMAGING LLC100%股權
格隆匯12月11日丨東誠藥業(002675.SZ)公佈,公司為完善產業佈局,根據董事會制定的發展戰略,加快打造國內核醫藥領域領先的產業平台,併為公司創造新的利潤增長點,實現公司的可持續發展。公司下屬公司米度(南京)生物技術有限公司(以下簡稱"買方"或"米度生物")於 2022 年 12月 10 日與 Gilles Tamagnan、 Molecular Neuroimaging Holdings LLC、 KennethMarek、Bill (Piu) Chan、David Alagille、Rebecca Evans、顧朱勤(以下簡稱"賣方")簽署了《股份購買協議》,以3020萬美元的交易金額收購賣方持有的 XINGIMAGING LLC(以下簡稱"標的公司")100%股權。
據悉,標的公司是一家核藥轉化及臨牀試驗影像CRO服務公司,利用新型PET藥品的製備質控技術、利用新型PET藥品的PET掃描服務及影像閲片管理經驗,協助國際藥企在臨牀試驗期間精準影像診斷CRO服務。主要服務包括新型PET藥品中試轉化;臨牀試驗伴隨診斷的新型PET藥品生產製備;新型PET藥品PET/CT影像掃描服務;PET影像閲片管理服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.